Rebiotix Senior Management
A dedicated team of veterans with deep experience in the pharmaceutical and medical device industries provide the leadership needed to advance our MRT™ drug platform at Rebiotix Inc., a Ferring Company. Their passion for addressing patient needs drives the clinical and scientific innovation that is the hallmark of our development programs.
Lee Jones, Founder, President & CEO
Lee Jones is the Founder, and the former President and Chief Executive Officer of Rebiotix Inc., a Ferring Company. Rebiotix is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.
Ms. Jones has over 30 years of experience as a medical technology executive and entrepreneur in large and small companies and academia. With Rebiotix as her first foray into biotechnology, Lee is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT). The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection.
Before joining Rebiotix, Ms. Jones was the Chief Administrative Officer of the Schulze Diabetes Institute at the University of Minnesota. She is also the former President and Chief Executive Officer of Inlet Medical, a privately held medical device company that she grew to profitability prior to its sale to CooperSurgical in 2006. Prior to Inlet, she spent 14 years at Medtronic where she developed and commercialized several innovative products, including InterStim – a surgically implanted neurostimulation device for urinary incontinence that opened up new markets for the company.
Ms. Jones has served on several public and private boards and is currently on the board of Electromed Inc., on the University of Minnesota’s Office of Technology Commercialization advisory board, and on the board of Medical Alley Association, an industry association. She is a member of the Sofia Angel Investment Fund and is an advisor to several small companies. Ms. Jones has a BS in Chemical Engineering from the University of Minnesota and an Executive Management degree from the Carlson School of Management at the University of Minnesota. She currently serves as the Senior Advisor for Ferring for the development and advancement of the company’s microbiome platform.
Greg Fluet, Chief Operating Officer and Site Head
Greg Fluet is the Chief Operating Officer and Site Head for Rebiotix, a Ferring Company. Mr. Fluet has been on the team at Rebiotix since 2016, including serving as Chief Business Officer until its acquisition by Ferring Pharmaceuticals in April 2018.
Prior to joining the microbiome space, Mr. Fluet had a strategic consulting practice focusing on startup life science companies. He also serves on the board of Electromed (NYSE: ELMD), a medical device company focused on airway clearance technologies. He had previously served as Chief Executive Officer at Urologix, Inc., then a public company, from 2012 to January 2016. He also served as its interim Chief Financial Officer from August 2014 to May 2015, and as its Executive Vice President and Chief Operating Officer from 2008 to 2012. Prior to Urologix, Mr. Fluet served as an associate at Sapient Capital Management, LLC, a healthcare focused venture capital fund. He received his Bachelor of Science degree in Mechanical Engineering from Stanford University.
Ken F. Blount, PhD, Chief Scientific Officer and Vice President of Microbiome Research
Ken Blount, PhD, is the Chief Scientific Officer for Rebiotix Inc., a Ferring Company, as well as Ferring’s Vice President of Microbiome Research. Dr. Blount is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics.
Prior to joining Rebiotix/Ferring, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridioides difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Lindy L. Bancke, PharmD, Head of Clinical Development
Lindy Bancke, Pharm.D., is the Head of Clinical Development at Rebiotix Inc., a Ferring Company. She joined Rebiotix in 2018 with a strong background in clinical development and strategic leadership at biotech and mid-size pharmaceutical companies. Dr. Bancke’s clinical and program leadership experience spans first-in-human studies to global Phase 3 trials, as well as products with orphan designation, fast track status, and unique regulatory pathways.
Prior to joining Rebiotix, Dr. Bancke spent 10 years at Upsher-Smith Laboratories, leading clinical trials and research strategy, as well as cross-functional development programs for both ANDA and NDA products. Most recently, she was the Clinical and Development Program Lead at Proximagen, a privately-held biotech company focused on small molecule drug discovery and development. At Proximagen, Dr. Bancke led an early-phase neuro-oncology program, as well as a late-stage epilepsy product preparing for NDA submission. Dr. Bancke received her undergraduate degree in biology from the University of Nebraska–Lincoln and earned a PharmD from the University of Nebraska Medical Center, after which she completed a post-doctoral fellowship in clinical research.
Nancy Timm, VP, Finance and Operations
Nancy Timm is the Vice President of Finance and Operations for Rebiotix Inc., a Ferring Company. Ms. Timm is a seasoned finance manager with over 20 years of experience working with small and start-up businesses. Prior to joining Rebiotix/Ferring, she held positions at the Institute for Environmental Assessment where she was CFO, and at Inlet Medical, a minimally invasive surgical technology company, among others. Inlet Medical was a privately held medical device company prior to being sold to CooperSurgical.
In her career, Ms. Timm was involved in the turnaround of a nearly bankrupt company, working with financial institutions, regulatory agencies and vendors in the process. Ms. Timm’s expertise includes strategic planning, financial reporting, annual audits, internal/external sales force management and mergers and acquisitions. She specializes in initiatives to streamline processes and increase the efficiency of business systems to improve bottom line results.
Karen E. Kuphal, PhD, MBA, PMP, Head of Regulatory Affairs
Karen E. Kuphal, PhD, MBA, PMP, is the Head of Regulatory Affairs for Rebiotix Inc., a Ferring Company. Dr. Kuphal has over 20 years of experience in advancing drug candidates within areas of rare disease and oncology. She is the Head of Regulatory Affairs at Rebiotix Inc, a Ferring Company, where she leads the team in advancing ground-breaking microbiota-based therapeutics.
Prior to joining Rebiotix/Ferring, Dr. Kuphal worked within Oncology Regulatory Science and Strategy at AstraZeneca, where she played a major role in AstraZeneca’s first success in FDA’s Real Time Oncology Review (RTOR) and “Orbis” programs, evidenced by the approval of Calquence within 2 months of submission. She also served as a Portfolio Manager within Biologics Development at Bristol-Myers Squibb (BMS). Dr. Kuphal has held leadership positions at Cote Orphan Consulting (a boutique regulatory consulting service for orphan-based products), Sigma-Tau Pharmaceuticals (now Leadiant Biosciences), and Cardinal Health Specialty (Regulatory) Services. Dr. Kuphal obtained her MBA from The George Washington University, with an emphasis in business analytics, and currently holds a PMP certification from the Project Management Institute. She completed her PhD from the University of Kansas in Exercise Physiology, with post-doctoral training at the University of Missouri-Kansas City in Pharmacology.
Tom Willard, MBA, VP of Upstream Marketing and Market Strategy
Tom Willard, MBA, is the Vice President of Upstream Marketing and Market Strategy for Rebiotix Inc., a Ferring Company. Mr. Willard brings over 30 years of commercial experience to the team. Mr. Willard’s experience covers a variety of therapeutic areas, including gastroenterology, infectious disease, urology, CNS/Neurology, oncology, immunology, and Women’s Health.
Mr. Willard has led commercial teams for pre-launch, launch, and co-promotion initiatives for both large and small companies in the pharmaceutical and biotech arenas, as well as providing commercial strategy to improve a company’s value. Additionally, Mr. Willard’s experience includes strategic brand planning, business development, market research, and product platform strategy as part of pre-approval packages, new market entries and product life cycle management.
Mr. Willard received his undergraduate degree in Microbiology and Immunology from Purdue University, as well as his MBA in Marketing/Corporate Strategy from Clemson University.